Shares of Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) have been assigned an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy recommendation.

Brokerages have set a 1-year consensus target price of $8.00 for the company and are forecasting that the company will post ($0.13) earnings per share for the current quarter, according to Zacks. Zacks has also given Pieris Pharmaceuticals an industry rank of 91 out of 265 based on the ratings given to related companies.

Separately, Roth Capital reiterated a “buy” rating and set a $6.00 target price on shares of Pieris Pharmaceuticals in a research report on Friday, August 5th.

A number of large investors have recently modified their holdings of the company. BlackRock Fund Advisors bought a new stake in shares of Pieris Pharmaceuticals during the second quarter worth approximately $113,000. Frontier Wealth Management LLC bought a new stake in shares of Pieris Pharmaceuticals during the second quarter worth approximately $137,000. Sabby Management LLC raised its stake in shares of Pieris Pharmaceuticals by 132.7% in the first quarter. Sabby Management LLC now owns 175,000 shares of the company’s stock worth $333,000 after buying an additional 99,792 shares in the last quarter. BVF Inc. IL bought a new stake in shares of Pieris Pharmaceuticals during the second quarter worth approximately $389,000. Finally, Lombard Odier Asset Management USA Corp raised its stake in shares of Pieris Pharmaceuticals by 20.3% in the second quarter. Lombard Odier Asset Management USA Corp now owns 3,166,915 shares of the company’s stock worth $5,099,000 after buying an additional 533,965 shares in the last quarter. 45.79% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) opened at 1.67 on Tuesday. The company has a 50 day moving average of $1.63 and a 200-day moving average of $1.79. The company’s market capitalization is $71.91 million. Pieris Pharmaceuticals has a 12-month low of $1.26 and a 12-month high of $3.08.

Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings data on Wednesday, August 10th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. Pieris Pharmaceuticals had a negative net margin of 346.01% and a negative return on equity of 52.21%. The company earned $1.07 million during the quarter. On average, equities analysts anticipate that Pieris Pharmaceuticals will post ($0.55) EPS for the current fiscal year.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

5 Day Chart for NASDAQ:PIRS

Get a free copy of the Zacks research report on Pieris Pharmaceuticals (PIRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.